AHL23 Antibody
Description
Product Overview
The AHL23 Antibody (Product Code: CSB-PA210817XA01DOA) is a polyclonal antibody developed against the Arabidopsis thaliana (Mouse-ear cress) AHL23 protein. It is commercially available in two sizes (2 ml or 0.1 ml) and targets the protein encoded by the Uniprot accession O23620 .
| Parameter | Specification |
|---|---|
| Target Protein | AHL23 (AT-HOOK MOTIF NUCLEAR LOCALIZED PROTEIN 23) |
| Host Species | Arabidopsis thaliana (Mouse-ear cress) |
| Uniprot ID | O23620 |
| Antibody Type | Polyclonal |
| Applications | Not explicitly stated in available sources |
| Validation Data | No direct validation data reported in reviewed sources |
Biological Context of AHL Proteins in Arabidopsis
AHL (AT-HOOK MOTIF NUCLEAR LOCALIZED) proteins are plant-specific transcription factors involved in regulating growth, development, and stress responses. While AHL23 itself is not discussed in the provided research articles, related AHL family members (e.g., AHL9, AHL27) are implicated in chromatin remodeling and gene expression modulation .
Research Findings and Applications
-
Antibody Validation Practices: Large-scale databases like the Validated Antibody Database (VAD) emphasize the importance of knockout studies and orthogonal validation methods (e.g., siRNA, GFP-tagged proteins) .
-
General AHL Research: Studies on other AHL antibodies (e.g., anti-AHL9, anti-AHL27) highlight their use in chromatin immunoprecipitation (ChIP) and protein localization assays in plant models .
Limitations and Future Directions
-
Data Gaps: No functional studies or validation data (e.g., Western blot, immunofluorescence) for AHL23 Antibody are available in the reviewed sources.
-
Research Opportunities: Future work could explore its utility in studying AHL23’s role in plant development or stress responses, leveraging techniques like ChIP-seq or CRISPR knockout lines.
References to Antibody Validation Resources
For rigorous validation, researchers are advised to consult:
Product Specs
Target Background
Q&A
Here’s a curated collection of FAQs for researchers working with the AHL23 antibody, structured to address both foundational and advanced scientific inquiries. The answers integrate methodologies, validation strategies, and analytical frameworks from peer-reviewed studies and technical guidelines.
Advanced Research Questions
How to resolve discrepancies in AHL23 binding affinity between in vitro and in vivo systems?
What computational pipelines enable de novo design of AHL23-derived antibodies?
-
AI-driven frameworks: Train models on NGS-derived VH/VL pairs (e.g., 4.25 × 10^12 combinations) to predict high-affinity binders .
-
Epitope-focused screening: Use cryo-EM or homology models (for unresolved targets) to guide in silico maturation .
-
Validation: Test top candidates in BLI/SPR and cell-based neutralization assays (e.g., SARS-CoV-2 pseudovirus) .
How to troubleshoot AHL23 cross-reactivity in multiplexed assays?
-
Epitope masking: Pre-incubate samples with non-overlapping antibodies to block shared epitopes .
-
Differential dilution: Titrate AHL23 to isolate signal thresholds for closely related isoforms .
-
Structural analysis: Perform HDX-MS to identify regions of unintended paratope flexibility .
Data Analysis & Interpretation
How to statistically validate AHL23’s binding kinetics across experimental replicates?
-
Global fitting: Apply a 1:1 binding model to SPR/BLI datasets pooled across buffer/serum conditions .
-
Error weighting: Use Bayesian inference to account for variability in low-affinity measurements (KD > 100 nM) .
